~~<i id='1175E8247D'><strike id='1175E8247D'><tt id='1175E8247D'><pre id='1175E8247D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

author：entertainment 2025-08-12 08:30:20 - browse：39

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

focus

hotspot

focus

entertainment

focus

SteffenTrumpf/picturealliance/GettyImagesWASHINGTON— NovoNordisk’snewlywonpermissiontomarkettheheart

WSS

How to save health care price transparency rules

Eli Lilly, Pfizer, and others want in on the online prescription market

Medicare coverage of Wegovy, once blocked, now looks possible

How digital therapeutics firms are pivoting after Pear's bankruptcy

WuXi out of biotech trade group, U.S. and China relations to blame

Amid AI frenzy, a top HHS official's quest to create safeguards

leisure time

leisure time

focus

Dobbs anniversary: the lost opportunity of abortion as health care

FDA advisers back CAR

The cancer drug shortage isn’t new — and neither are the solutions

Steward Health Care Massachusetts hospitals face fiscal disaster

Supreme Court strikes down use of affirmative action

As AI in medicine takes off, can 'human in the loop' prevent harm?

Wildfire smoke exposes gaps in outdoor worker protections

FDA clears AI tool for detecting skin cancer

Peter Hotez and the public health issue of online harassment

Dewpoint Therapeutics lays off staff after losing partnerships

hotspot

HHS secretary Becerra pressed on Change HealthCare cyberattack

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Steward Health Care Massachusetts hospitals face fiscal disaster

Medicare Advantage today, explained in one chart

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

hotspot

focus

entertainment

focus